Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.
Animals
Antigens, Tumor-Associated, Carbohydrate
/ genetics
Antineoplastic Agents
/ pharmacology
Ascitic Fluid
/ metabolism
Carcinogenesis
/ genetics
Carcinogenicity Tests
Cell Line, Tumor
/ drug effects
Chile
Cisplatin
/ pharmacology
Clone Cells
/ drug effects
DNA Fingerprinting
Deoxycytidine
/ analogs & derivatives
Epithelial Cells
/ metabolism
Gallbladder Neoplasms
/ genetics
Gene Expression Profiling
Genes, erbB-2
/ genetics
Humans
Indians, South American
/ genetics
Keratin-19
/ genetics
Keratin-7
/ genetics
Male
Mice, Inbred NOD
Middle Aged
Receptor, ErbB-2
/ genetics
Sequence Analysis, RNA
Tumor Cells, Cultured
Tumor Suppressor Protein p53
/ genetics
Gemcitabine
Ascites
Cancer cell lines
Gallbladder cancer
Gene expression profile
Native American ancestry
Journal
Biological research
ISSN: 0717-6287
Titre abrégé: Biol Res
Pays: England
ID NLM: 9308271
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
received:
11
10
2019
accepted:
06
04
2020
entrez:
16
4
2020
pubmed:
16
4
2020
medline:
28
4
2020
Statut:
epublish
Résumé
Gallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In Chile, GBC represents the second cause of cancer-related death among women. We describe here the establishment of three novel cell lines derived from the ascitic fluid of a Chilean GBC patient, who presented 46% European, 36% Mapuche, 12% Aymara and 6% African ancestry. After immunocytochemical staining of the primary cell culture, we isolated and comprehensively characterized three independent clones (PUC-GBC1, PUC-GBC2 and PUC-GBC3) by short tandem repeat DNA profiling and RNA sequencing as well as karyotype, doubling time, chemosensitivity, in vitro migration capability and in vivo tumorigenicity assay. Primary culture cells showed high expression of CK7, CK19, CA 19-9, MUC1 and MUC16, and negative expression of mesothelial markers. The three isolated clones displayed an epithelial phenotype and an abnormal structure and number of chromosomes. RNA sequencing confirmed the increased expression of cytokeratin and mucin genes, and also of TP53 and ERBB2 with some differences among the three cells lines, and revealed a novel exonic mutation in NF1. The PUC-GBC3 clone was the most aggressive according to histopathological features and the tumorigenic capacity in NSG mice. The first cell lines established from a Chilean GBC patient represent a new model for studying GBC in patients of Native American descent.
Sections du résumé
BACKGROUND
BACKGROUND
Gallbladder cancer (GBC) is the most common tumor of the biliary tract. The incidence of GBC shows a large geographic variability, being particularly frequent in Native American populations. In Chile, GBC represents the second cause of cancer-related death among women. We describe here the establishment of three novel cell lines derived from the ascitic fluid of a Chilean GBC patient, who presented 46% European, 36% Mapuche, 12% Aymara and 6% African ancestry.
RESULTS
RESULTS
After immunocytochemical staining of the primary cell culture, we isolated and comprehensively characterized three independent clones (PUC-GBC1, PUC-GBC2 and PUC-GBC3) by short tandem repeat DNA profiling and RNA sequencing as well as karyotype, doubling time, chemosensitivity, in vitro migration capability and in vivo tumorigenicity assay. Primary culture cells showed high expression of CK7, CK19, CA 19-9, MUC1 and MUC16, and negative expression of mesothelial markers. The three isolated clones displayed an epithelial phenotype and an abnormal structure and number of chromosomes. RNA sequencing confirmed the increased expression of cytokeratin and mucin genes, and also of TP53 and ERBB2 with some differences among the three cells lines, and revealed a novel exonic mutation in NF1. The PUC-GBC3 clone was the most aggressive according to histopathological features and the tumorigenic capacity in NSG mice.
CONCLUSIONS
CONCLUSIONS
The first cell lines established from a Chilean GBC patient represent a new model for studying GBC in patients of Native American descent.
Identifiants
pubmed: 32293552
doi: 10.1186/s40659-020-00282-7
pii: 10.1186/s40659-020-00282-7
pmc: PMC7158131
doi:
Substances chimiques
Antigens, Tumor-Associated, Carbohydrate
0
Antineoplastic Agents
0
Keratin-19
0
Keratin-7
0
Tumor Suppressor Protein p53
0
Deoxycytidine
0W860991D6
Receptor, ErbB-2
EC 2.7.10.1
Cisplatin
Q20Q21Q62J
Gemcitabine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13Subventions
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1170893
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1171463
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1151008
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 11180987
Organisme : Fondo Nacional de Desarrollo Científico y Tecnológico
ID : 1160800
Organisme : Instituto Milenio
ID : IMII P09/016-F
Organisme : Dirección de Investigación Medicina-UC (CL)
ID : 16-240
Organisme : Comisión Nacional de Investigación Científica y Tecnológica
ID : 21140027
Références
Cancer Cell Int. 2017 Feb 8;17:20
pubmed: 28194091
Nucleic Acids Res. 2010 Sep;38(16):e164
pubmed: 20601685
Medicine (Baltimore). 2015 Dec;94(50):e2286
pubmed: 26683959
Histopathology. 2011 Nov;59(5):822-31
pubmed: 22092393
Oncol Lett. 2018 Aug;16(2):1917-1923
pubmed: 30008884
CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64
pubmed: 11760569
Int J Oncol. 1997 Jun;10(6):1251-5
pubmed: 21533512
Sci Rep. 2017 Jun 22;7(1):4020
pubmed: 28642461
Histopathology. 2009 Aug;55(2):218-29
pubmed: 19490172
PLoS Genet. 2017 May 25;13(5):e1006756
pubmed: 28542165
Mol Oncol. 2018 Nov;12(11):1838-1855
pubmed: 30133130
Hepatogastroenterology. 1999 Jul-Aug;46(28):2240-5
pubmed: 10521973
Virchows Arch. 2016 Apr;468(4):431-9
pubmed: 26758058
Cell Res. 2020 Jan;30(1):34-49
pubmed: 31811277
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Histol Histopathol. 2017 Jun;32(6):585-596
pubmed: 27672051
Hum Pathol. 1996 Apr;27(4):360-5
pubmed: 8617479
Dis Markers. 2016;2016:9421571
pubmed: 27190429
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
Oncotarget. 2018 Nov 2;9(86):35666-35675
pubmed: 30479696
Cell Rep. 2020 Jan 21;30(3):793-806.e6
pubmed: 31968254
Int J Cancer. 2006 Apr 1;118(7):1591-602
pubmed: 16397865
Int J Cancer. 2001 Jul 20;95(4):232-9
pubmed: 11400116
Int J Oncol. 2004 May;24(5):1189-96
pubmed: 15067341
Breast Cancer Res Treat. 2016 Jul;158(1):99-111
pubmed: 27318853
J Pathol. 2005 Jul;206(3):356-65
pubmed: 15892172
Rev Med Chil. 2000 Mar;128(3):251-8
pubmed: 10962865
J Surg Oncol. 2012 Jan;105(1):97-103
pubmed: 21815153
Cancer Biomark. 2019;24(2):183-193
pubmed: 30689556
Cancer Res. 2001 Oct 1;61(19):6971-6
pubmed: 11585718
Genome Res. 2010 Sep;20(9):1297-303
pubmed: 20644199
Nat Immunol. 2016 Nov;17(11):1273-1281
pubmed: 27595232
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
J Clin Oncol. 2012 Nov 10;30(32):3932-8
pubmed: 22987085
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
N Am J Med Sci. 2012 Jul;4(7):293-9
pubmed: 22866265
Mod Pathol. 2013 May;26(5):677-84
pubmed: 23238628
Clin Epidemiol. 2014 Mar 07;6:99-109
pubmed: 24634588
Jpn J Cancer Res. 1995 Jul;86(7):662-9
pubmed: 7559084
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
J Pathol. 1999 May;188(1):30-7
pubmed: 10398137
Neoplasia. 2017 Nov;19(11):857-867
pubmed: 28930697
Mod Pathol. 2012 Jul;25(7):938-48
pubmed: 22388760
Pathol Int. 2004 Aug;54(8):576-84
pubmed: 15260848
Hum Pathol. 2012 Oct;43(10):1755-63
pubmed: 22542127
Elife. 2018 Aug 03;7:
pubmed: 30074477
BMC Cancer. 2019 Dec 30;19(1):1266
pubmed: 31888563
Ecancermedicalscience. 2016 Dec 21;10:704
pubmed: 28105075
Oncol Rep. 2020 Apr;43(4):1147-1158
pubmed: 32020235
Hum Cell. 1988 Mar;1(1):95-7
pubmed: 3154020
J Surg Oncol. 2006 Jun 15;93(8):665-9
pubmed: 16724349
Histopathology. 1997 Sep;31(3):226-30
pubmed: 9354892
Kaohsiung J Med Sci. 2006 Feb;22(2):53-9
pubmed: 16568721
Oncotarget. 2016 Oct 4;7(40):64910-64920
pubmed: 27626311
Pathol Oncol Res. 2014 Apr;20(2):409-15
pubmed: 24178677
Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6
pubmed: 11454421
World J Gastroenterol. 2009 Sep 28;15(36):4511-7
pubmed: 19777609
Int J Urol. 2005 Jul;12(7):654-61
pubmed: 16045558
HPB (Oxford). 2004;6(3):174-80
pubmed: 18333072
Pathol Int. 1997 Aug;47(8):525-30
pubmed: 9293532
J Gastroenterol Hepatol. 2004 Jul;19(7):812-8
pubmed: 15209630
J Clin Oncol. 2005 Jan 1;23(1):154-64
pubmed: 15625370
Oncol Rep. 2012 Mar;27(3):775-82
pubmed: 22134783
Nat Genet. 2014 Aug;46(8):872-6
pubmed: 24997986
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Eur J Surg Oncol. 2005 Oct;31(8):891-6
pubmed: 15922536
Biomed Res. 2014;35(5):295-302
pubmed: 25355436
Nature. 2015 Oct 1;526(7571):68-74
pubmed: 26432245
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
J Am Coll Surg. 2001 Oct;193(4):380-3
pubmed: 11584965
Adv Med Sci. 2018 Sep;63(2):296-300
pubmed: 29803118
Gastrointest Cancer Res. 2007 Nov;1(6):221-7
pubmed: 19262900
Clin Proteomics. 2019 Oct 30;16:37
pubmed: 31687002
Breast Cancer Res Treat. 2017 Nov;166(2):447-457
pubmed: 28799059
Br J Cancer. 2002 Jul 15;87(2):187-93
pubmed: 12107841
World J Gastrointest Oncol. 2011 Apr 15;3(4):49-59
pubmed: 21528090
Gan. 1980 Aug;71(4):574-5
pubmed: 7429092
Genome Res. 2009 Sep;19(9):1655-64
pubmed: 19648217
PLoS One. 2016 Nov 9;11(11):e0166067
pubmed: 27829047
Bioinformatics. 2011 Mar 15;27(6):863-4
pubmed: 21278185
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncology. 2016;91(6):354-360
pubmed: 27784017
Virchows Arch. 2010 Sep;457(3):299-307
pubmed: 20665045
J Gastrointest Cancer. 2019 Dec;50(4):848-854
pubmed: 30155833
Cancer Biol Med. 2019 Feb;16(1):89-100
pubmed: 31119049
Saudi J Gastroenterol. 2013 Jan-Feb;19(1):34-9
pubmed: 23319036
Clin Cancer Res. 2001 May;7(5):1333-42
pubmed: 11350903
Oncotarget. 2017 Jul 28;8(41):70508-70520
pubmed: 29050298
Oncotarget. 2017 Aug 3;8(52):90315-90326
pubmed: 29163831
Gastrointest Cancer Res. 2014 Mar;7(2):42-8
pubmed: 24799970
BMC Cancer. 2019 Sep 18;19(1):928
pubmed: 31533654
Cancer Res. 2007 Apr 15;67(8):3794-800
pubmed: 17440093